James Posey, MD
Medical Oncology · Philadelphia, PANPI 1427082734
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,895 of the $8,034 with a category attached, or 73.4%. 7 manufacturers reported payments, led by Pfizer at 37.3% of the total. Reporting peaked in 2023 at $6,146 and has fallen 99.6% since, to $27 in 2025.
Across 15 payments — averaging $535.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$3K
- Seagen Inc.$3K
- Eli Lilly$2K
- AbbVie$246
- Angiodynamics, Inc.$192
- Ipsen Biopharmaceuticals, Inc$189
- plus $12 from 1 others
Across 44 payments — averaging $7451.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$151K
- EMD Serono, Inc.$58K
- E.r. Squibb & Sons, L.L.C.$54K
- Bristol Myers Squibb$33K
- Beigene, Ltd.$20K
- Astrazeneca UK Limited$9K
- plus $2K from 1 others
What the payments were for
- Consulting fees$5,89573%
- Speaking & faculty fees$1,50019%
- Food & beverage$6398%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 2 | $3,000 |
| Seagen Inc. | 2 | $2,520 |
| Eli Lilly | 1 | $1,875 |
| AbbVie(2 entities) | 6 | $246 |
| Angiodynamics, Inc. | 1 | $192 |
| Ipsen Biopharmaceuticals, Inc | 2 | $189 |
| Foundation Medicine, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Nanoknife$192
- BOTOX COSMETIC$124
- ONIVYDE$111
How this compares
$8,034 in reported general payments places this provider in the 65th percentile of 238 medical oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Philadelphia
- Carl JunePhiladelphia$9M
- Shayma KazmiPhiladelphia$619K
- Marcia BrosePhiladelphia$260K
- Adam CohenPhiladelphia$239K
- Daniel HallerPhiladelphia$227K
- Edith MitchellPhiladelphia$220K
- Elizabeth PlimackPhiladelphia$190K
- Alexander PerlPhiladelphia$176K
- Martin EdelmanPhiladelphia$157K
- Jean-Pierre IssaPhiladelphia$147K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.